Priya Nigam on Muck Rack

Priya Nigam

As seen in: Benzinga, MSN, Business Insider, Markets Insider, MSN España, Aol, Yahoo Finance, Yahoo Finance Singapore, Yahoo Finance UK, Yahoo Finanzas Spain, Taylor & Francis Online and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Priya

Contact Priya, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

General Mills 'Less Bad' Outlook Leaves Analyst Unimpressed - General Mills (NYSE:GIS)

|
By Priya Nigam
| Benzinga
The General Mills Thesis: Moskow reiterated a Hold rating and raised the price target from $31 to $32. Management indicated an improvement in sales. However, they are "hesitant on growth," he said. Check out other analyst stock ratings. General Mills guided to organic sales growth of -1.5% to +0.5%. This implies that fiscal 2027 would be "less bad" than the disappointing 2% decline in fiscal 2026, the analyst stated.
Open in Who Shared Issue with article?

FactSet Research Systems: Rising AI Adoption Bodes Well for Subscription Value Growth, Says Analyst - Fac

|
By Priya Nigam
| Benzinga
• FactSet Research Systems stock is moving in positive territory. What’s pushing FDS stock higher? The FactSet Research Systems Analyst: Analyst Ashish Sabadra reiterated a Sector Perform rating and price target of $240. The FactSet Research Systems Thesis: The company’s third-quarter organic ASV grew $35.4 million sequentially, exceeding consensus of $30 million, with the growth rate accelerating to 7.1% year-over-year, from 6.7% in the previous quarter, Sabadra said in the note.
Open in Who Shared Issue with article?

Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst - Hims & Hers Healt

|
By Priya Nigam
| Benzinga
The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc‘s (NYSE:HIMS) peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained a Neutral rating while raising the price target to $36 from $25. The FDA released briefing materials this week ahead of Pharmacy Compounding Advisory Committee (PCAC) meetings reviewing the seven peptides, Lutz said. Check out other analyst stock ratings.
Open in Who Shared Issue with article?
See all 6,243 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified